Optibrium Secures Strategic Financing to Boost Product Development
Optibrium has secured a multi-million-pound financing package with Shawbrook, a UK specialist bank supporting high-growth businesses. This funding will accelerate the development of Optibrium’s software and AI-driven solutions for molecular design, expanding its global footprint in pharmaceutical and biotech markets.
The investment focuses on enhancing core technologies across Optibrium’s software portfolio. Key development areas include generative chemistry, collaborative design, and 3D molecular modelling. These improvements aim to increase the speed and efficiency of drug discovery processes for global research teams.
Funding Structure and Market Context
Shawbrook structured the deal around Annual Recurring Revenue (ARR), providing immediate capital along with committed facilities for future growth. The computer-aided drug discovery (CADD) sector is growing fast, driven by advanced software tools that reduce cost and time for drug developers.
Market research forecasts the global CADD market will grow from $4.21 billion in 2024 to $13.08 billion by 2034, at a compound annual growth rate (CAGR) of 12%. This financing positions Optibrium to capitalize on this expanding market.
Company Overview and Adoption
Founded in 2009 and operating in the UK and US, Optibrium combines scientific research with computational methods to deliver software for compound design, optimisation, and data analysis. Over 160 organisations worldwide currently use Optibrium’s platforms to improve decision-making early in drug discovery.
Statements from Key Stakeholders
- Peter Ralph, Partner at Kester Capital: “Optibrium has shown exceptional growth and innovation since our initial investment. This financing supports their strategic goals and keeps them at the forefront of drug discovery technology.”
- Ally Henderson, CFO at Optibrium: “The financing validates the value our technology delivers to pharmaceutical research. Shawbrook’s flexible package supports both our current needs and long-term plans, benefiting our expanding customer base.”
- Jack Longden, Director at Shawbrook: “Optibrium’s growth since 2021 is impressive. We are pleased to provide a financing solution that supports their technology advancement and global expansion ambitions.”
This funding round not only strengthens Optibrium’s product development but also positions them well for sustained growth in a competitive and evolving market.
Your membership also unlocks:
